litlas
Log inCreate account

Michael S. Gordon

Active 1980–2025

126
Papers
25,669
Citations
78
h-index
122
i10-index

Citations

Citations per year for Michael S. Gordon1984: 1 citations1990: 2 citations1991: 7 citations1992: 28 citations1993: 23 citations1994: 17 citations1995: 17 citations1996: 24 citations1997: 32 citations1998: 39 citations1999: 54 citations2000: 62 citations2001: 37 citations2002: 58 citations2003: 85 citations2004: 85 citations2005: 87 citations2006: 90 citations2007: 108 citations2008: 118 citations2009: 120 citations2010: 111 citations2011: 131 citations2012: 144 citations2013: 204 citations2014: 219 citations2015: 345 citations2016: 419 citations2017: 425 citations2018: 441 citations2019: 1,020 citations2020: 1,142 citations2021: 1,072 citations2022: 881 citations2023: 621 citations2024: 798 citations2025: 392 citations2026: 9 citations1985–1989: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 4,148 citing papers, 29.5% of this breakdownChina: 1,660 citing papers, 11.8% of this breakdownItaly: 736 citing papers, 5.2% of this breakdownUnited Kingdom: 729 citing papers, 5.2% of this breakdownFrance: 713 citing papers, 5.1% of this breakdownGermany: 653 citing papers, 4.7% of this breakdownSpain: 467 citing papers, 3.3% of this breakdownJapan: 443 citing papers, 3.2% of this breakdownCanada: 413 citing papers, 2.9% of this breakdownAustralia: 376 citing papers, 2.7% of this breakdownNetherlands: 348 citing papers, 2.5% of this breakdownSwitzerland: 324 citing papers, 2.3% of this breakdown
0%29.5%Other 21.6%

Institutions

Fields

  • Medicine65.8%
  • Biochemistry, Genetics and Molecular Biology20.9%
  • Immunology and Microbiology7.3%
  • Engineering2.8%
  • Computer Science0.7%
  • Neuroscience0.6%
  • Other1.9%

Topics

  • Cancer Immunotherapy and Biomarkers14.2%
  • Immunotherapy and Immune Responses6.2%
  • CAR-T cell therapy research4.2%
  • Immune Cell Function and Interaction3.2%
  • Melanoma and MAPK Pathways2.1%
  • Immune cells in cancer2%
  • Other68.1%

Coauthors

All papers

Open in search
  1. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

    Authors: Roy S. Herbst, Jean‐Charles Soria, Marcin Kowanetz, Gregg Fine, Omid Hamid, Michael S. Gordon, Jeffery A. Sosman, David F. McDermott, John D. Powderly, Scott Gettinger, Holbrook E. Kohrt, Leora Horn, Donald P. Lawrence, Sandra Rost, Maya K. Leabman, Yuanyuan Xiao, Ahmad Mokatrin, Hartmut Koeppen, Priti S. Hegde, Ira Mellman, Daniel S. Chen, F. Stephen Hodi - Nature 2014 cited by 5,302

  2. Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer

    Authors: Leisha A. Emens, Cristina Cruz, Joseph P. Eder, Fadi Braiteh, Cathie T. Chung, Sara M. Tolaney, Irene Kuter, Rita Nanda, Philippe A. Cassier, Jean‐Pierre Delord, Michael S. Gordon, Ehab A. ElGabry, Ching-Wei Chang, Indrani Sarkar, William Grossman, Carol O’Hear, Marcella Fassò, Luciana Molinero, Peter Schmid - JAMA Oncology 2018 cited by 793

  3. Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer

    Authors: Mary L. Disis, Matthew H. Taylor, Karen Kelly, J. Thaddeus Beck, Michael S. Gordon, Kathleen M. Moore, Manish R. Patel, Jorge Chaves, Haeseong Park, Alain C. Mita, Erika Hamilton, Christina M. Annunziata, H. Grote, Anja von Heydebreck, Jaspreet Singh Grewal, Vikram K. Chand, James L. Gulley - JAMA Oncology 2019 cited by 427

  4. Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAF V600E-Mutant Colorectal Cancer

    Authors: Ryan B. Corcoran, Thierry André, Chloé E. Atreya, Jan H.M. Schellens, Takayuki Yoshino, Johanna C. Bendell, Antoine Hollebecque, Autumn J. McRee, Salvatore Siena, Gary Middleton, Kei Muro, Michael S. Gordon, Josep Tabernero, Rona Yaeger, Peter J. O’Dwyer, Y. Humblet, Filip De Vos, A. Scott Jung, Jan C. Brase, Savina Jaeger, Severine Bettinger, Bijoyesh Mookerjee, Fatima Rangwala, Eric Van Cutsem - Cancer Discovery 2018 cited by 583

  5. Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors

    Authors: Tae Won Kim, Philippe L. Bédard, Patricia LoRusso, Michael S. Gordon, Johanna C. Bendell, Do‐Youn Oh, Myung‐Ju Ahn, Elena Garralda, Sandra P. D’Angelo, Jayesh Desai, F. Stephen Hodi, Zev A. Wainberg, Jean‐Pierre Delord, Phillippe A. Cassier, Andrés Cervantes, Marta Gil-Martín, Benjamin Wu, Namrata S. Patil, Yanling Jin, Tien Hoang, Diana Mendus, Xiaohui Wen, Raymond D. Meng, Byoung Chul Cho - JAMA Oncology 2023 cited by 63

  6. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies.

    Authors: Michael B. Atkins, Michael J. Robertson, Michael S. Gordon, M T Lotze, M DeCoste, J.-B. Dubois, Jerome Ritz, Alan B. Sandler, Howard Edington, Pamela D. Garzone, J W Mier, Christine Canning, Linda A. Battiato, Hideaki Tahara, Matthew L. Sherman - 1997 cited by 590

  7. Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial

    Authors: Andrea J. Bullock, Benjamin L. Schlechter, Marwan Fakih, Apostolia M. Tsimberidou, Joseph E. Grossman, Michael S. Gordon, Breelyn A. Wilky, Agustin Pimentel, Daruka Mahadevan, Ani Sarkis Balmanoukian, Rachel E. Sanborn, Gary K. Schwartz, Ghassan K. Abou‐Alfa, Neil H Segal, Bruno Bockorny, Justin C. Moser, Sunil Sharma, Jaymin Patel, Wei Wu, Dhan Chand, Katherine Rosenthal, Gabriel Mednick, Chloé Delépine, Tyler J. Curiel, Justin Stebbing, Heinz‐Josef Lenz, Steven O’Day, Anthony B. El-Khoueiry - Nature Medicine 2024 cited by 110

  8. First-in-Humans Imaging with 89Zr-Df-IAB22M2C Anti-CD8 Minibody in Patients with Solid Malignancies: Preliminary Pharmacokinetics, Biodistribution, and Lesion Targeting

    Authors: Neeta Pandit‐Taskar, Michael A. Postow, Matthew D. Hellmann, James J. Harding, Christopher A. Barker, Joseph A. O’Donoghue, Martha Ziolkowska, Shutian Ruan, Serge K. Lyashchenko, Frank Tsai, Michael D. Farwell, Tara C. Mitchell, Ron Korn, William Le, Jason S. Lewis, Wolfgang Weber, Deepak Behera, Ian A. Wilson, Michael S. Gordon, Anna M. Wu, Jedd D. Wolchok - Journal of Nuclear Medicine 2019 cited by 262

  9. Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial

    Authors: Manish R. Patel, John Ellerton, Jeffrey R. Infante, Manish Agrawal, Michael S. Gordon, Raid Aljumaily, Carolyn D. Britten, Luc Dirix, Keun‐Wook Lee, Mathew Taylor, Patrick Schöffski, Ding Wang, Alain Ravaud, Arnold B. Gelb, Junyuan Xiong, Galit Rosen, James L. Gulley, Andrea B. Apolo - The Lancet Oncology 2017 cited by 588

  10. CD8-targeted PET Imaging of Tumor Infiltrating T cells in Patients with Cancer: A Phase I First-in-Human Study of 89Zr-Df-IAB22M2C, a Radiolabeled anti-CD8 Minibody

    Authors: Michael D. Farwell, Raymond F. Gamache, Hasan Babazada, Matthew D. Hellmann, James J. Harding, Ron Korn, Alessandro Mascioni, William Le, Ian A. Wilson, Michael S. Gordon, Anna M. Wu, Gary A. Ulaner, Jedd D. Wolchok, Michael A. Postow, Neeta Pandit‐Taskar - Journal of Nuclear Medicine 2021 cited by 124

  11. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial

    Authors: Jeffrey R. Infante, Leslie A. Fecher, Gerald S. Falchook, Sujatha Nallapareddy, Michael S. Gordon, Carlos Becerra, Douglas J. DeMarini, Donna S. Cox, Yanmei Xu, Shannon R. Morris, Vijay Peddareddigari, Ngocdiep T. Le, Lowell L. Hart, Johanna C. Bendell, Gail Eckhardt, Razelle Kurzrock, Keith T. Flaherty, Howard A. Burris, Wells A. Messersmith - The Lancet Oncology 2012 cited by 558

  12. Safety and Efficacy of Durvalumab (MEDI4736), an Anti–Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer

    Authors: Christophe Massard, Michael S. Gordon, Sunil Sharma, Saeed Rafii, Zev A. Wainberg, Jason J. Luke, Tyler J. Curiel, Gerardo Colón‐Otero, Omid Hamid, Rachel E. Sanborn, Peter H. O’Donnell, Alexandra Drakaki, Winston Tan, John F. Kurland, Marlon C. Rebelatto, Xiaoping Jin, John A. Blake-Haskins, Ashok Gupta, Neil H. Segal - Journal of Clinical Oncology 2016 cited by 845

  13. A Phase I Study of LY3009120, a Pan-RAF Inhibitor, in Patients with Advanced or Metastatic Cancer

    Authors: Ryan J. Sullivan, Antoine Hollebecque, Keith T. Flaherty, Geoffrey I. Shapiro, Jordi Rodon Ahnert, Michael Millward, Wei Zhang, Ling Gao, Amanda K. Sykes, Melinda D. Willard, Danni Yu, Andrew E. Schade, KrisAnne Crowe, Daniel L. Flynn, Michael D. Kaufman, James R. Henry, Sheng-Bin Peng, Karim A. Benhadji, Ilaria Conti, Michael S. Gordon, Ramón V. Tiu, David S. Hong - Molecular Cancer Therapeutics 2019 cited by 87

  14. Results from a phase 1a/1b study of botensilimab (BOT), a novel innate/adaptive immune activator, plus balstilimab (BAL; anti-PD-1 antibody) in metastatic heavily pretreated microsatellite stable colorectal cancer (MSS CRC).

    Authors: Anthony B. El-Khoueiry, Marwan Fakih, Michael S. Gordon, Apostolia M. Tsimberidou, Andrea J. Bullock, Breelyn A. Wilky, Jonathan C. Trent, Kim Margolin, Daruka Mahadevan, Ani Sarkis Balmanoukian, Rachel E. Sanborn, Gary K. Schwartz, Bruno Bockorny, Justin C. Moser, Joseph E. Grossman, W.I. Ortuzar Feliu, Katherine Rosenthal, Steven O’Day, Heinz‐Josef Lenz, Benjamin L. Schlechter - Journal of Clinical Oncology 2023 cited by 55

  15. PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma

    Authors: Antoni Ribas, Alain P. Algazi, Paolo A. Ascierto, Marcus O. Butler, Sunandana Chandra, Michael S. Gordon, Leonel F. Hernandez‐Aya, Donald P. Lawrence, Jose Lutzky, Wilson H. Miller, Katie M. Campbell, Bruno Delafont, Shannon Marshall, Nancy K. Mueller, Caroline Robert - Nature Communications 2020 cited by 88

  16. Atezolizumab, an Anti–Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study

    Authors: David F. McDermott, Jeffrey A. Sosman, Mario Sznol, Christophe Massard, Michael S. Gordon, Omid Hamid, John D. Powderly, Jeffrey R. Infante, Marcella Fassò, Yan V. Wang, Wei Zou, Priti S. Hegde, Gregg Fine, Thomas Powles - Journal of Clinical Oncology 2016 cited by 558

  17. Phase I Dose-Escalation Study of Recombinant Human Apo2L/TRAIL, a Dual Proapoptotic Receptor Agonist, in Patients With Advanced Cancer

    Authors: Roy S. Herbst, S. Gail Eckhardt, Razelle Kurzrock, Scot Ebbinghaus, Peter J. O’Dwyer, Michael S. Gordon, William Novotny, Meredith A. Goldwasser, Tanyifor M. Tohnya, Bert L. Lum, Avi Ashkenazi, Adrian M. Jubb, David S. Mendelson - Journal of Clinical Oncology 2010 cited by 440

  18. Safety and Clinical Activity of Atezolizumab in Patients with Metastatic Castration-Resistant Prostate Cancer: A Phase I Study

    Authors: Daniel P. Petrylak, Yohann Loriot, David R. Shaffer, Fadi Braiteh, John D. Powderly, Lauren C. Harshman, Paul Conkling, Jean‐Pierre Delord, Michael S. Gordon, Joseph W. Kim, Indrani Sarkar, Kobe Yuen, Edward E. Kadel, Sanjeev Mariathasan, Carol O’Hear, Sujata Narayanan, Marcella Fassò, Susheela Carroll, Thomas Powles - Clinical Cancer Research 2021 cited by 79

  19. Randomized Phase III Trial of High-Dose Interleukin-2 Versus Subcutaneous Interleukin-2 and Interferon in Patients With Metastatic Renal Cell Carcinoma

    Authors: David F. McDermott, Meredith M. Regan, Joseph I. Clark, Lawrence E. Flaherty, Geoffrey R. Weiss, Theodore F. Logan, John M. Kirkwood, Michael S. Gordon, Jeffrey A. Sosman, Marc S. Ernstoff, Christopher Tretter, Walter J. Urba, John W. Smith, Kim Margolin, James W. Mier, Jared Gollob, Janice P. Dutcher, Michael B. Atkins - Journal of Clinical Oncology 2004 cited by 819

  20. Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer

    Authors: Martin H. Voss, Michael S. Gordon, Monica Mita, Brian I. Rini, Vicky Makker, Teresa Macarulla, David C. Smith, Andrés Cervantes, Igor Puzanov, Роберто Пили, Ding Wang, Shadia I. Jalal, Shubham Pant, Manish R. Patel, Rachel Neuwirth, Aaron Enke, Yaping Shou, Farhad Sedarati, Douglas V. Faller, Howard A. Burris - British Journal of Cancer 2020 cited by 90

  21. First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors

    Authors: Tae Won Kim, Howard A. Burris, Maria J. de Miguel, Michael J. Pishvaian, Yung‐Jue Bang, Michael S. Gordon, Ahmad Awada, D. Ross Camidge, F. Stephen Hodi, Grant A. McArthur, Wilson H. Miller, Andrés Cervantes, Laura Q.M. Chow, Alexander M. Lesokhin, Annemie Rutten, Mario Sznol, Deepali Rishipathak, Shang‐Chiung Chen, Eric Stefanich, Tony Pourmohamad, Maria Inêz Padula Anderson, Jeong Kim, Mahrukh Huseni, Ina Rhee, Lillian L. Siu - Clinical Cancer Research 2022 cited by 82

  22. Abstract CT301: A phase Ib study to evaluate RO7198457, an individualized Neoantigen Specific immunoTherapy (iNeST), in combination with atezolizumab in patients with locally advanced or metastatic solid tumors

    Authors: Juanita Lopez, D. Ross Camidge, Marco Iafolla, Sylvie Rottey, Martin Schüler, Matthew D. Hellmann, Ani Sarkis Balmanoukian, Luc Dirix, Michael S. Gordon, Ryan J. Sullivan, Brian S. Henick, Charles G. Drake, Kit Man Wong, Patricia LoRusso, Patrick A. Ott, Lawrence Fong, Aglaia Schiza, Jeffery Yachnin, Christian H. Ottensmeier, Fadi Braiteh, Johanna C. Bendell, Rom S. Leidner, George A. Fisher, Guy Jérusalem, Laura Molenaar‐Kuijsten, Marcus Schmidt, Scott A. Laurie, Raid Aljumaily, Achim Rittmeyer, Eelke Gort, Ignacio Melero, Lars Müeller, Rachel Lubong Sabado, Patrick Twomey, Jack Y.J. Huang, M. Yadav, Jingbin Zhang, Felicitas Mueller, Evelyna Derhovanessian, Uğur Şahin, Özlem Türeci, Thomas Powles - Cancer Research 2020 cited by 59

  23. Phase Ia Study of Anti-NaPi2b Antibody–Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Patients with Non–Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer

    Authors: David E. Gerber, Jeffrey R. Infante, Michael S. Gordon, Sarah B. Goldberg, Miguel Martín, Enriqueta Felip, Maria Martinez‐García, Joan H. Schiller, David R. Spigel, Julie Cordova, Valerie Westcott, Yulei Wang, David S. Shames, YounJeong Choi, Robert S. Kahn, Randall Dere, Divya Samineni, Jian Xu, Kedan Lin, Katie Wood, Stephanie Royer‐Joo, Vanessa Lemahieu, Eva Schuth, Anjali Vaze, Daniel Maslyar, Eric W. Humke, Howard A. Burris - Clinical Cancer Research 2019 cited by 53

  24. Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial

    Authors: Toni K. Choueiri, James Larkin, Mototsugu Oya, Fiona Thistlethwaite, Marcella Martignoni, Paul Nathan, Thomas Powles, David F. McDermott, Paul B. Robbins, David D. Chism, Daniel Cho, Michael B. Atkins, Michael S. Gordon, Sumati Gupta, Hirotsugu Uemura, Yoshihiko Tomita, Anna Compagnoni, Camilla Fowst, Alessandra di Pietro, Brian I. Rini - The Lancet Oncology 2018 cited by 260